Applicant, as named in the Orange Book
Harrow Eye
Harrow Inc · Nasdaq: HROW
Company and ticker: cliffwatch mapping, checked against SEC EDGAR · SEC filings
Next listed expiry: Nevanac on 31 Jan 2027. 9 products with live protection, 7 without.
Products with listed protection
| Drug | Earliest generic entry |
|---|---|
| Nevanac NDA 021862 nepafenac | 31 Jan 2027 patent, carve-out possible |
| Tobradex St NDA 050818 dexamethasone; tobramycin | 3 Aug 2028 patent |
| Verkazia NDA 214965 cyclosporine | 2 Jun 2029 patent |
| Triesence NDA 022048 triamcinolone acetonide | 17 Dec 2029 patent |
| Ilevro NDA 203491 nepafenac | 31 Mar 2032 patent |
| Zerviate NDA 208694 cetirizine hydrochloride | 9 Jan 2033 patent |
| Byqlovi NDA 218158 clobetasol propionate | 9 May 2036 patent |
| Iheezo NDA 216227 chloroprocaine hydrochloride | 14 May 2039 patent |
| Vevye NDA 217469 cyclosporine | 1 Apr 2042 patent |
Recent events
- Verkazia · Generic approved · ANDA 211909, AmnealApproved 28 Nov 2025Detected 25 Oct 2026
- Verkazia · Generic approved · ANDA 219288, Jiangsu AnbisonApproved 1 Jun 2026Detected 25 Oct 2026
- Verkazia · Generic approved · ANDA 209064, Twi PharmsApproved 21 Jan 2026Detected 25 Oct 2026
- Nevanac · Enters 12-month window basis: patent, carve-out possibleListed date 31 Jan 2027Detected 24 Oct 2026
Products without listed protection (7)
| Drug | Earliest generic entry |
|---|---|
| Flarex NDA 019079 fluorometholone acetate | open now no listed protection |
| Iopidine NDA 019779 apraclonidine hydrochloride | open now no listed protection |
| Iopidine NDA 020258 apraclonidine hydrochloride | open now no listed protection |
| Maxidex NDA 013422 dexamethasone | open now no listed protection |
| Maxitrol NDA 050023 dexamethasone; neomycin sulfate; polymyxin b sulfate | open now no listed protection |
| Natacyn NDA 050514 natamycin | open now no listed protection |
| Vigamox NDA 021598 moxifloxacin hydrochloride | open now no listed protection |